Chardan analyst Geulah Livshits raised the firm’s price target on Palvella Therapeutics (PVLA) to $110 from $73 and keeps a Buy rating on the shares after the company announced Qtorin pitavastatin for disseminated superficial actinic porokeratosis as its second product candidate. With a 50K U.S. cases, no FDA approved therapies, and mechanistic validation from academic studies using other topical statins, the program has a strong chance of technical success and a presents a “robust” commercial opportunity, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics price target raised to $97 from $65 at TD Cowen
- Palvella Therapeutics price target raised to $200 from $120 at Cantor Fitzgerald
- Palvella Therapeutics price target raised to $190 from $95 at H.C. Wainwright
- Buy Rating for Palvella Therapeutics: Innovative Approach and Strategic Development in Rare Dermatological Treatments
- Strategic Expansion of Palvella Therapeutics’ QTORIN Platform Targets Unmet Needs in Rare Skin Conditions